[ad_1]
A cocktail of combined monoclonal antibodies produced by Regeneron and Roche has been shown to reduce hospitalization or death in COVID-19 patients by 70%, according to a press release on Tuesday. The combination therapy, dubbed REGEN-COV, was being evaluated in a phase 3 trial involving high-risk outpatient COVID-19 patients.
REGEN-COV includes casirivimab in combination with imdevimab and has already received emergency use authorization from the FDA in the United States. and who are at high risk of developing severe symptoms or the need for hospitalization.
The currently authorized dose is 1200 mg casirivimab and 1200 mg imdevimab administered together as a single infusion within 10 days of symptom onset.
SINOVAC SAYS COVID-19 VACCINE IS SAFE FOR CHILDREN UNDER 3 YEARS OF AGE
The press release, issued by Regeneron Pharmaceuticals, Inc., also noted that the therapy reduced the duration of symptoms and that an additional Phase 2 trial had reduced viral load in patients receiving low doses of REGEN- VOC. The trial saw patients receiving 300 mg intravenously and 600 mg subcutaneously, with researchers noting reductions in the first seven days comparable to those given at intravenous doses of 2400 mg and 1200 mg.
REGEN-COV is made up of casirivimab with imdevimab, and has already received emergency use clearance from the FDA in the United States.
(iStock)
“With approximately 60,000 people newly diagnosed in the United States each day and 40,000 still in hospital due to COVID-19, we are committed to working with government, healthcare providers and others to support rapid adoption. and widespread REGEN-COV if any patients, “George D. Yancopoulos, MD, Ph.D., president and scientific director of Regeneron, said in the press release.” We will discuss the new data promptly with regulatory authorities. and request that the 1,200 mg dose be added to the US emergency use authorization, so that the planned supply of REGEN-COV is available to treat even more patients. “
CLICK HERE FOR FULL CORONAVIRUS COVERAGE
The company said there were ongoing trials involving REGEN-COV, including one in the UK studying the impact it could have on hospital patients. Another assesses prevention of COVID-19 in household contacts of those infected.
[ad_2]
Source link